| scholarly article | Q13442814 |
| P50 | author | Frank W. Stahnisch | Q5490175 |
| Alex John London | Q42395099 | ||
| Alan Fine | Q50419442 | ||
| Timothy Ramsay | Q58377261 | ||
| Jonathan Kimmelman | Q60642521 | ||
| Marina Elena Emborg | Q61304553 | ||
| P2093 | author name string | Mark Bernstein | |
| Bernard Ravina | |||
| P2860 | cites work | Why most published research findings are false | Q21092395 |
| Functional recovery in parkinsonian monkeys treated with GDNF | Q24312738 | ||
| Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease | Q28187904 | ||
| Design, power, and interpretation of studies in the standard murine model of ALS | Q28268686 | ||
| Core assessment program for intracerebral transplantations (CAPIT) | Q28295664 | ||
| AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease | Q28304068 | ||
| Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders | Q29614754 | ||
| Can the pharmaceutical industry reduce attrition rates? | Q29616077 | ||
| Incidence of symptomatic hemorrhage after stereotactic electrode placement | Q30444891 | ||
| Pooling of animal experimental data reveals influence of study design and publication bias | Q30918723 | ||
| What are the implications of optimism bias in clinical research? | Q33233736 | ||
| Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial | Q33623861 | ||
| Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). | Q33704308 | ||
| Recent developments in gene transfer: risk and ethics | Q33709989 | ||
| Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease | Q33739160 | ||
| The ethical problems with sham surgery in clinical research | Q33739165 | ||
| Recommendations for standards regarding preclinical neuroprotective and restorative drug development | Q33785562 | ||
| Subthalamic GAD gene therapy in a Parkinson's disease rat model | Q34154186 | ||
| Emergency medicine animal research: does use of randomization and blinding affect the results? | Q34202311 | ||
| Recommendations for clinical trial evaluation of acute stroke therapies. | Q34300670 | ||
| Benefits, risks and ethical considerations in translation of stem cell research to clinical applications in Parkinson's disease | Q34576574 | ||
| Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials | Q34617625 | ||
| Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial | Q34640765 | ||
| Results from a phase I safety trial of hAADC gene therapy for Parkinson disease | Q34656075 | ||
| Nonhuman primate models of Parkinson's disease | Q34665820 | ||
| Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions | Q34770260 | ||
| Sample size determination | Q34976175 | ||
| Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment | Q35111748 | ||
| Comparison of treatment effects between animal experiments and clinical trials: systematic review | Q35610097 | ||
| Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke | Q36036681 | ||
| Operative techniques and morbidity with subthalamic nucleus deep brain stimulation in 100 consecutive patients with advanced Parkinson's disease | Q36226290 | ||
| Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia | Q36260781 | ||
| Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions | Q36498773 | ||
| Lost in translation: treatment trials in the SOD1 mouse and in human ALS. | Q36735871 | ||
| Clinical attrition due to biased preclinical assessments of potential efficacy. | Q36851581 | ||
| Complications in subthalamic nucleus stimulation surgery for treatment of Parkinson's disease. Review of 272 procedures | Q36906715 | ||
| Contributions of non-human primates to neuroscience research | Q37122421 | ||
| Treatment of Parkinson's disease with trophic factors | Q37131259 | ||
| The adult human brain in preclinical drug development | Q37212752 | ||
| Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. | Q40464992 | ||
| Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. | Q40678042 | ||
| Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys | Q40702469 | ||
| Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease | Q40846012 | ||
| Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach | Q40870377 | ||
| Essential myoclonus and myoclonic dystonia | Q41018229 | ||
| Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain | Q42280576 | ||
| Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial | Q42650874 | ||
| Effects of unilateral subthalamic and pallidal deep brain stimulation on fine motor functions in Parkinson's disease | Q43964521 | ||
| Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease | Q45858560 | ||
| Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. | Q45859568 | ||
| Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism | Q45859700 | ||
| Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models. | Q45882831 | ||
| Trends in acute ischemic stroke trials through the 20th century | Q46087072 | ||
| Risk factors for hemorrhage during microelectrode-guided deep brain stimulator implantation for movement disorders | Q46518059 | ||
| Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. | Q46884563 | ||
| Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys | Q48197305 | ||
| Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys | Q48325968 | ||
| Studying neurosurgical implants for Parkinson disease: a question of design | Q48389029 | ||
| Articulating and responding to uncertainties in clinical research | Q48693284 | ||
| Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. | Q50751408 | ||
| Volunteering for early phase gene transfer research in Parkinson disease. | Q50943814 | ||
| Empirical evidence of bias in the design of experimental stroke studies: a metaepidemiologic approach. | Q52920486 | ||
| Placebos that harm: sham surgery controls in clinical trials. | Q53414315 | ||
| Core assessment program for intracerebral transplantation in Huntington's disease (CAPIT-HD) | Q60618652 | ||
| Translation of research evidence from animals to humans | Q79220569 | ||
| Neuroprotection in Parkinson's disease: and now for something completely different? | Q79365348 | ||
| Neuroprotection in Parkinson's disease: an elusive goal | Q80052020 | ||
| A call for clinically driven experimental design in assessing neuroprotection in experimental Parkinsonism | Q80185925 | ||
| Neuroscience: Standard model | Q81752942 | ||
| Alzheimer research forum live discussion: mice on trial? Issues in the design of drug studies | Q83214263 | ||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| medical ethics | Q237151 | ||
| research ethics | Q1132684 | ||
| P304 | page(s) | 1893-901 | |
| P577 | publication date | 2009-10-15 | |
| P1433 | published in | Movement Disorders | Q1486418 |
| P1476 | title | Launching invasive, first-in-human trials against Parkinson's disease: ethical considerations | |
| P478 | volume | 24 |
| Q28728201 | A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in parkinsonian monkeys |
| Q21563449 | Can animal models of disease reliably inform human studies? |
| Q45804789 | Challenges to Informed Consent in First-In-Human Trials Involving Novel Treatments: A Case Study of Parkinson's Disease |
| Q36275707 | Established patterns of animal study design undermine translation of disease-modifying therapies for Parkinson's disease |
| Q58281682 | Ethical Criteria for Human Trials of Stem-Cell-Derived Dopaminergic Neurons in Parkinson's Disease |
| Q38617877 | Ethical principles for novel therapies in veterinary practice |
| Q35788038 | Extending clinical equipoise to phase 1 trials involving patients: unresolved problems |
| Q40688627 | First-in-human HIV-remission studies: reducing and justifying risk |
| Q90364838 | In vitro modeling of the neurovascular unit: advances in the field |
| Q58255075 | Intracranial Stem Cell-Based Transplantation: Reconsidering the Ethics of Phase 1 Clinical Trials in Light of Irreversible Interventions in the Brain |
| Q28732112 | Intraoperative intracerebral MRI-guided navigation for accurate targeting in nonhuman primates |
| Q36014074 | Novel therapies, high-risk pediatric research, and the prospect of benefit: learning from the ethical disagreements |
| Q34786764 | Preclinical assessment of stem cell therapies for neurological diseases. |
| Q33851241 | Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty |
| Q58172885 | Refining Ethical Guidelines for Early Clinical Trials of Pluripotent Stem-Cell-Derived Therapeutics for Parkinson's Disease |
| Q35893072 | Research ethics. Beyond access vs. protection in trials of innovative therapies |
| Q30371423 | Risk of surgical delivery to deep nuclei: a meta-analysis |
| Q47879705 | Studying the lay of the land: views and experiences of professionals in the translational pluripotent stem cell field |
| Q39502650 | Tomorrow, interrupted? Risk, ethics, and medical advance in gene transfer |
| Q30417520 | Why primate models matter |
| Q36157306 | α-Synuclein and nonhuman primate models of Parkinson's disease |
Search more.